药石科技(300725) - 2022 Q3 - 季度财报

Financial Performance - Revenue for Q3 2022 reached ¥450,058,731.03, an increase of 59.83% compared to the same period last year[5] - Net profit attributable to shareholders was ¥96,523,773.69, up 57.87% year-on-year[5] - Net profit excluding non-recurring items was ¥91,757,829.72, reflecting a 64.72% increase compared to the previous year[5] - Operating income increased by 107.42% to ¥19,198,057.75 compared to ¥9,255,542.90 in the same period last year[11] - Total operating revenue for the current period reached ¥1,184,702,109.49, a significant increase from ¥902,929,920.72 in the previous period, representing a growth of approximately 31.2%[32] - Net profit for the current period was ¥261,286,132.90, compared to ¥451,168,056.54 in the previous period, reflecting a decrease of approximately 42.2%[34] - Earnings per share for the current period were reported at 1.2570, compared to 2.2399 in the previous period, indicating a decline of approximately 43.8%[34] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥4,955,539,732.77, a 41.31% increase from the end of the previous year[5] - Current liabilities totaled approximately 1.28 billion yuan, compared to 788.88 million yuan in the previous year[28] - Long-term liabilities amounted to approximately 1.12 billion yuan, significantly higher than 90.33 million yuan in the previous year[28] - The company reported a total equity of approximately 2.55 billion yuan as of September 30, 2022[28] - The company’s total liabilities and equity increased to ¥4,955,539,732.77 from ¥3,506,922,491.19, reflecting a growth of about 41.3%[31] Cash Flow - Cash flow from operating activities for the year-to-date was ¥186,433,654.21, down 33.53% compared to the previous year[5] - Cash paid for purchasing goods and services increased by 38.58% to ¥596,044,900.65, primarily due to higher material procurement expenses[11] - Cash paid to employees surged by 79.20% to ¥352,418,090.14, reflecting an increase in workforce and salary expenses[11] - Cash received from borrowings rose significantly by 339.83% to ¥792,895,362.26, indicating increased bank loan amounts[11] - Cash paid for debt repayment increased by 240.48% to ¥409,679,206.00, reflecting higher repayments of due bank loans[11] - The company reported a net increase in cash and cash equivalents of $7,819,198.21, contrasting with a decrease of $374,555,376.31 in the prior period[41] Investment and Financing - Cash invested increased by 40.86% to ¥3,314,532,000.00, mainly due to higher purchases of financial products[11] - The company received cash from convertible bond fundraising amounting to ¥1,145,283,018.87, marking a new financing strategy[11] - Cash inflow from financing activities reached $1,938,178,381.13, a substantial rise from $180,273,159.65 in the previous period[41] - Net cash flow from financing activities improved to $1,004,307,342.88 from $40,005,468.30, reflecting a positive shift in financing operations[41] Research and Development - Research and development expenses rose by 48.79% to ¥121,203,263.82, indicating increased investment in innovation[10] - Research and development expenses increased to ¥121,203,263.82 from ¥81,457,397.06, marking a rise of approximately 48.8%[32] Shareholder Information - The total number of common shareholders at the end of the reporting period was 23,470, with the largest shareholder holding 20.69%[13] Revenue Breakdown - Revenue from the sub-block business reached 269 million yuan, a year-on-year increase of 44.19%[21] - CDMO revenue amounted to 909 million yuan, reflecting a year-on-year growth of 28.09%[21] - Domestic revenue was 372 million yuan, up 43.06% compared to the same period last year[21] - International revenue reached 812 million yuan, showing a year-on-year increase of 26.41%[21] - Overall gross margin for the first three quarters was 47.30%, slightly down from the previous year[21]